ECR AG, a member of exceet Group and a specialist for sophisticated electronic components and complex devices, has won an industrialization and production order from Biovotion AG for a new wearable vital signs platform for patient monitoring. In addition Biovotion announced that Jonathan Cool has joined Biovotion as President of Biovotion USA, the company’s expansion operation into the North American market.
Biovotion’s Vital Sign Monitoring platform aims to assist patients during the treatment process by continuously transmitting vital sign data, addressing growing requirements in terms of data continuity and data quality, as well as patient security in monitoring of chronically ill patients. A final prototype of the VSM is already expected to be available this year, and certification is likewise scheduled to begin in 2015. Series production at ECR in Switzerland will start in 2016. exceet Group will manufacture the new body monitor in its entirety, i.e. including the charging station, conduct all quality assurance testing and deliver the devices in ready-to-ship packaging.
“For such a demanding schedule, we needed a development and production partner with extensive practical experience in the medical device field, and one who can contribute rapid, maximum-quality support in terms of know-how and production capacities. And that’s exactly what we found in ECR AG. The icing on the cake is that we can also rely on the wide-ranging expertise and technologies of the other companies of exceet Group, particularly in the fields of miniaturization, data security, authentication, RFID and NFC,” says Andreas Caduff, CEO of Biovotion. “exceet gives us all the product realization competencies from a single source. That reduces development costs and shortens our time-to-market phase. For us, it’s an important advantage to have a company at our side that can offer all these competencies and has successfully proven them on the market.”
The VSM1 is the first body monitor of a new Biovotion series. The medical product enables continuous, motion-tolerant and thus robust monitoring of heartrate, blood oxygenation, skin temperature and other vital sign parameters – all in a highly user-friendly form, without a chest strep. The project was designed e.g. to monitor patients with chronic illnesses and is suited for uses in hospitals, but also for mobile patients and health-conscious individuals. The Biovotion VSM is worn on the upper arm. The captured medical data can be displayed on and intelligently processed by a variety of devices, e.g. smartphones or tablets.
New President of Biovotion USA
In addition Biovotion announced the appointment of Jonathan Cool as President of Biovotion USA. Jonathan is a serial entrepreneur with more than 30 years of experience in the startup, operations and management of medical device, bio-pharmaceutical and health care delivery companies, including, Molecular Devices, Human Genome Sciences, CardioNet, and Cygnus Therapeutic Systems among others. He also was managing partner of Foundation Medical Partners – a health care venture capital fund affiliated with the Cleveland Clinic for many years. Jonathan joins Biovotion after more than a year of working closely with the management team in the development of an international expansion strategy. “We are very pleased to have Jonathan join our team to develop Biovotion’s foot print in the US. His expertise in the field as well as experience will greatly help the company, its partners and customers to continue pursue attractive business opportunities in North America”, says Andreas Caduff, CEO of Biovotion.
Please login or sign up to comment.
Commenting guidelines